Myeloid Profiler DNA Panel
Myeloid Profiler DNA Panel
Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) are among the myeloid malignancies with an exceptionally complex and diverse genetic landscape. A wide range of genetic changes underlie many illnesses, affecting diagnosis, prognosis, and treatment choices. To face these diagnostic and therapeutic complexities, researchers and clinicians need a next-generation sequencing (NGS) for cancer platform that leaves no crucial variant undiscovered. The Uncoded Myeloid Profiler DNA Panel, a comprehensive myeloid mutation panel, meets this demand by providing a thorough and high-resolution method for genetic testing for cancer, allowing both researchers and clinicians to gain crucial insights into the entire range of myeloid cancers.
Why Is It Important to Analyze Myeloid Mutations?
Myeloid cancers are not caused by a single genetic event, they are driven by accumulations of mutations across many genes involved in cell signaling, DNA repair, apoptosis, and differentiation. This diversity of genetic lesions leads to highly variable clinical presentations and outcomes. The use of a myeloid malignancies mutation panel enhances the ability to detect these variations with precision.
- Precision in Diagnosis: Mutations in genes such as NPM1, FLT3, RUNX1, and ASXL1 drive not only initial disease classification, but also ongoing risk stratification and response prediction.
- Prognostic Value: Many myeloid gene mutations serve as markers for prognosis; for example, TP53 or RUNX1 mutations are associated with poor outcomes, while others impact therapy selection.
- Therapeutic Targets: Certain mutations (FLT3, IDH1/2, JAK2) are directly actionable with targeted therapies, facilitating precision medicine in oncology.
Major Challenges in Comprehensive Myeloid Profiling
Comprehensive profiling of myeloid conditions faces several significant challenges. The inherent variability and occurrence of overlapping or concurrent mutations necessitate a broad and inclusive approach to profiling. Identifying rare variants, typically found at low allele frequencies—requires high sensitivity, especially for early detection and monitoring of minimal residual disease (MRD). Furthermore, variations in specimens present another challenge, as the tumour content can differ greatly between bone marrow and peripheral blood, highlighting the need for reliable and efficient chemistry. Finally, the intricate nature of result interpretation demands sophisticated bioinformatics in cancer research to guarantee correct variant annotation and efficient clinical reporting. This is why advanced solutions such as a myeloid next generation sequencing panel are essential.
Applications for Myeloid Profiler DNA Panel
| Cat. No. | Reactions |
|---|---|
| UNONC/0507/024 | 24 |
| UNONC/0507/048 | 48 |
| UNONC/0507/096 | 96 |
- Store at -20°C to -15°C for long-term stability.
- Avoid repeated freeze-thaw cycles to maintain reagent integrity
Frequently Asked Questions
Curious about workflow, accuracy, or compatibility? Find all your answers here
What are the challenges of 16S V3-V4?
How does16S V3-V4 improve compliance?
Lorem ipsum dolor sit amet consectetur. Dolor aenean lorem integer nunc at nascetur enim. At porta eu imperdiet porta condimentum vitae in lacus. Amet placerat senectus justo integer nulla lobortis bibendum sed quam. Morbi consequat iaculis et est elementum in.
What is 16S V3-V4?
Lorem ipsum dolor sit amet consectetur. Dolor aenean lorem integer nunc at nascetur enim. At porta eu imperdiet porta condimentum vitae in lacus. Amet placerat senectus justo integer nulla lobortis bibendum sed quam. Morbi consequat iaculis et est elementum in.
How does16S V3-V4 improve compliance?
Lorem ipsum dolor sit amet consectetur. Dolor aenean lorem integer nunc at nascetur enim. At porta eu imperdiet porta condimentum vitae in lacus. Amet placerat senectus justo integer nulla lobortis bibendum sed quam. Morbi consequat iaculis et est elementum in.
Learn more about : Myeloid Profiler DNA Panel
